Skip to main content
OpenTrials
Completed

NCT Number: NCT03134586

Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease

The purpose of this study is to determine whether Non-invasive endoscopic procedures (pillcam colon capsule endoscopy, PCCE) and non-ionizing radiological modalities (MR enterocolonography, MREC and ultrasound, US) - offer a sufficiently high diagnostic validity in patients with suspected CD compared to the traditional invasive approach using ileocolonoscopy with biopsies as first line diagnostic modality

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sydvestjysk sygehus, Esbjerg, Denmark

Loading trial locations.

About this study

This is a prospective, blinded, multicenter study of the diagnostic validity, inter-observer agreement, image quality and subjective experience of discomfort with PCCE, MREC and US in patients with suspected CD. Ileocolonoscopy serves as the diagnostic gold standard. Patients are recruited from 3 centers in the Region of Southern Denmark managing adult patients with inflammatory bowel diseases. Each patient goes through a standardized work-up including medical history, physical examination, C-reactive protein, fecal calprotectin, ileocolonoscopy, PCCE, MREC and US. All examinations are reviewed and described in a standardized fashion. The radiologists and physicians describing PCCE, MREC, and US are blinded to the findings at ileocolonoscopy and the other imaging modalities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General criterion

All of the following:

  • Clinical suspicion of CD
  • Age > 15 years
  • Negative serologic markers for celiac disease, negative stool culture (or polymerase chain reaction) for pathogenic bacteria and a negative microscopy for intestinal parasites
  • Fecal calprotectin > 50 mg/kg
  • Signed informed consent

Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) associated with one or more of the following findings: (1) C-reactive protein (CRP) >5 mg/L, (2) thrombocytosis (> 400 x 109/L), anemia (hemoglobin < 7.0 mmol/L for women and < 8.0 mmol /L for men or a decrease > 0.5 mmol/L compared to the usual level), (3) prolonged fever (> 37.5 C for more than 2 weeks), (5) weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal abscess/fistula, or (7) a family history of inflammatory bowel disease.

Exclusion criteria

  • Acute bowel obstruction
  • Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion except prophylactic treatment with low dose Aspirin (≤ 150 mg per day)
  • Pregnancy or lactation
  • Alcohol or drug abuse
  • Known gastrointestinal disorder other than inflammatory bowel disease
  • Renal failure defined by a plasma-creatinine above the normal reference range
  • Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes MREC
  • Interpreter required or inability to understand the oral and written information
  • Colonoscopy contraindicated, performed within 3 months or unwillingness to go through colonoscopy

Treatment and study plan

Diagnostic imaging

Other

Primary outcomes

  1. Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD

    Time frame: 36 months

    Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD located in the terminal ileum and colon (per patient & per segment). Ileocolonoscopy serves as gold standard

  2. Correlation of disease severity

    Time frame: 36 months

    Correlation of disease severity assessed with PCCE, MREC, US and ileocolonoscopy

  3. Inter-observer agreement

    Time frame: 36 months

    Inter-observer agreement with PCCE, MREC, US and ileocolonoscopy

Secondary outcomes

  1. Diagnostic yield of proximal CD

    Time frame: 36 months

    Diagnostic yield of PCCE, MREC and US for CD located proximal to the terminal ileum

  2. Patients reported experience

    Time frame: 36 months

    Patients' subjective experience of discomfort during PCCE, MREC, US and ileocolonoscopy

  3. Interobserver PCCE

    Time frame: 36 months

    Sensitivity and specificity of PCCE with different reading protocols

  4. Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow

    Time frame: 36 months

    Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow (Limberg score): Sensitivity, specificity and correlation with endoscopic disease activity

Sponsors and collaborators

Lead sponsor

Esbjerg Hospital - University Hospital of Southern Denmark

Other

Collaborators

  • Odense University Hospital
  • Sygehus Lillebaelt

Registry information

Official study title

A Comparative Study of the Diagnostic Validity of Ultrasound, Magnetic Resonance Imaging and Capsule Endoscopy of Both the Small and Large Intestine in Suspected Crohn's Disease

Acronym: ANDI

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
May 1, 2017
Registry last updated
Nov 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.